Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer

Radiation is a standard treatment option for patients with liver cancer. Unfortunately, the tumour grows after radiation in many patients and radiation can harm normal tissues. A new treatment using a specialized radiation procedure called Stereotactic body radiotherapy (SBRT) may increase the chance to control liver cancer and reduce the chance of harm to normal tissues. SBRT allows radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. SBRT has become a routine treatment. Further research has found that specialized computer programs can possibly guide the selection of an appropriate SBRT dose. This is called radiobiological guidance. However, this has not yet been proven to improve outcomes and/or reduce toxicity. Therefore, the purpose of this study is to find out if SBRT at standard dose versus SBRT guided by radiobiological techniques is better for you and your liver cancer.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

1. Eligible patients include patients with any of the following:

   * Primary hepatobiliary cancer confirmed pathologically or,
   * Non-lymphoma liver metastases confirmed pathologically or,
   * Radiographic liver lesions most consistent with metastases, in a patient with known pathologically proven non-lymphoma cancer and a previously negative CT or MRI of the liver or,
   * Hepatocellular carcinoma diagnosed with vascular enhancement of the lesion consistent with hepatocellular carcinoma, and with an elevated AFP, in the setting of cirrhosis or chronic hepatitis.
2. ≤ 5 liver lesions measurable on a contrast-enhanced liver CT or MRI performed within 90 days prior to study entry.
3. Primary liver lesion or liver metastases measuring ≤ 25 cm.
4. Extrahepatic cancer is permitted if liver involvement is judged to be life-limiting
5. No contraindications to radiotherapy
6. Patient must be judged medically or surgically unresectable
7. Zubrod Performance Scale = 0-3
8. Age \> 18
9. Systemic treatment including multikinase inhibitors and immunotherapy are allowed.

   Multikinase inhibitors must be held 2 weeks prior to radiation and may be restarted 1 week post radiation.
10. Previous liver resection or ablative therapy is permitted
11. Chemotherapy must be completed at least 2 weeks prior to radiation therapy and not planned to be administered for at least 1 week (for anthracyclines at least 4 weeks) after completion of treatment.
12. Life expectancy \> 6 months.
13. Women of childbearing potential and male participants must practice adequate contraception.

Exclusion Criteria:

1. Severe cirrhosis or liver failure defined as Child Pugh \>B7
2. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
3. Severe, active co-morbidity, defined as limiting the patient's life to less than 6 months
4. Active hepatitis or clinically significant liver failure. Treated hepatitis is permitted.
5. Pregnancy, nursing women, or women of childbearing potential, and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be teratogenic.

• RESULTGhouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017 May 29;16:1. doi: 10.4103/jcar.JCar_9_16. eCollection 2017. PMID 28694740
• RESULTDe P, Dryer D, Otterstatter MC, Semenciw R. Canadian trends in liver cancer: a brief clinical and epidemiologic overview. Curr Oncol. 2013 Feb;20(1):e40-3. doi: 10.3747/co.20.1190. PMID 23443230
• RESULTJarnagin W, Chapman WC, Curley S, D'Angelica M, Rosen C, Dixon E, Nagorney D; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010 Jun;12(5):302-10. doi: 10.1111/j.1477-2574.2010.00182.x. PMID 20590903
• RESULTKlein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):22-32. doi: 10.1016/j.ijrobp.2012.08.043. Epub 2012 Dec 6. PMID 23219567
• RESULTMazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):693-9. doi: 10.1056/NEJM199603143341104. PMID 8594428
• RESULTLo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002 May;35(5):1164-71. doi: 10.1053/jhep.2002.33156. PMID 11981766
• RESULTShim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int. 2005 Dec;25(6):1189-96. doi: 10.1111/j.1478-3231.2005.01170.x.